Octreotide treatment of idiopathic pulmonary fibrosis: A proof-of-concept study

European Respiratory Journal

Volumn 39, Issue 3, 2012, Pages 772-775

  Crestani, B ^a,b,c   Chapron, J ^b   Wallaert, B ^g   Bergot, E ^h   Delaval, P ⁱ   Israel Biet, D ^c   Lacronique, J ^d   Monnet, I ^j   Reynaud Gaubert, M ^k   Tazi, A ^e   Lebtahi, R ^b   Debray, M P ^b   Brauner, M ^l   Dehoux, M ^b,c   Dornic, Q ^b,f   Aubier, M ^a,b,c   Mentre, F ^b,f   Duval, X ^b,f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d Hôpital Saint Louis ^*  (France)

^e SAINT LOUIS HOSPITAL   (France)

^f INSERM   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CHU CÔTE DE NACRE   (France)

ⁱ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^k HÔPITAL SAINTE MARGUERITE   (France)

^l AVICENNE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ETANERCEPT; MONOCYTE CHEMOTACTIC PROTEIN 1; OCTREOTIDE; PIRFENIDONE; PLACEBO; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

BINDING AFFINITY; BRONCHITIS; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LETTER; LUNG FUNCTION TEST; PRIORITY JOURNAL; RISK FACTOR; SMOKING HABIT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FRANCE; GASTROINTESTINAL AGENTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; OCTREOTIDE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84860320360     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00113011     Document Type: Letter

References (10)

1. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
2. Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 2008; 63: 251-258. (Pubitemid 351373721)
3. Lebtahi R, Moreau S, Marchand-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006; 47: 1281-1287. (Pubitemid 47544880)
4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
5. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
6. van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2010; 23: 515-520.
7. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548. (Pubitemid 37088596)
8. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
9. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
10. Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008; 177: 190-194.